By Louis Garguilo, Chief Editor, Outsourced Pharma
Conventional wisdom holds that startups, virtuals, biotechs, and other smaller pharma companies struggle to compete with their Big Pharma counterparts for capabilities, capacity, pricing, and even attention at CDMOs. But is this always the case? Does it have to be?
Outsourced Pharma brought together a panel of experts at sponsor companies to discuss specifically how small biopharma can compete for attention at CDMOs.